Payment overview · 2025
General Payments
$281.37
14 reported records · 10 companies
Healthcare provider profile · identity verified
Ryan Burdick, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · FRESNO, CA · NPI 1881970572
Verified facts
What the public records show
CMS Open Payments records show Ryan Burdick, FNP received $281.37 in general payments during 2025 across 14 reported records.
Lilly USA, LLC accounted for 27.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $76.63 | 27.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.85 | 12.7% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.62 | 9.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $26.40 | 9.4% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $26.35 | 9.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.97 | 8.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.26 | 7.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.69 | 7.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.50 | 4.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8.10 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $281.37 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $76.63 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.85 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $27.62 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $26.40 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $26.35 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $8.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 124 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 546 | 168 |
| Metformin Hcl | Metformin Hcl | 342 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 95 |
| Losartan Potassium | Losartan Potassium | 272 | 71 |
| Lisinopril | Lisinopril | 253 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 229 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 203 | 58 |
| Gabapentin | Gabapentin | 194 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 48 |
| Famotidine | Famotidine | 157 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 154 | 78 |
| Omeprazole | Omeprazole | 151 | 46 |
| Montelukast Sodium | Montelukast Sodium | 132 | 28 |
| Jardiance | Empagliflozin | 124 | 39 |
| Ibuprofen | Ibuprofen | 119 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 40 |
| Furosemide | Furosemide | 107 | 36 |
| Trazodone Hcl | Trazodone Hcl | 102 | 29 |
| Baclofen | Baclofen | 90 | 30 |
| Tramadol Hcl | Tramadol Hcl | 89 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 22 |
| Ozempic | Semaglutide | 82 | 22 |
| Allopurinol | Allopurinol | 80 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 17 |
| Simvastatin | Simvastatin | 70 | 16 |
| Sertraline Hcl | Sertraline Hcl | 68 | 17 |
| Azelastine Hcl | Azelastine Hcl | 67 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 15 |
| Glimepiride | Glimepiride | 59 | 16 |
| Rybelsus | Semaglutide | 58 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | suppressed |
| Chlorthalidone | Chlorthalidone | 52 | 15 |
| Clotrimazole | Clotrimazole | 52 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 23 |
| Januvia | Sitagliptin Phosphate | 48 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 21 |
| Alendronate Sodium | Alendronate Sodium | 46 | 14 |
| Carvedilol | Carvedilol | 45 | 14 |
| Eliquis | Apixaban | 45 | 13 |
| Naproxen | Naproxen | 44 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 43 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 41 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 14 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 37 | 16 |
| Hydrocortisone | Hydrocortisone | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | 12 |
| Atenolol | Atenolol | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | 12 |
| Finasteride | Finasteride | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | 11 |
| Alprazolam | Alprazolam | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 12 |
| Prednisone | Prednisone | 28 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 22 |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $281.37 · 14 records | Lilly USA, LLC | ACCRUFER, AIRSUPRA, Dexcom G6 Transmitter, JARDIANCE, Kerendia, MOUNJARO, NUZYRA, RELISTOR, TZIELD, VOQUEZNA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error